The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
Amid reports of Immigration and Customs Enforcement (ICE) at hospitals and President Trump's reversal of policy protecting "sensitive locations" like hospitals, KFF's Health Tracking Poll finds that a majority of the public say they are concerned about the Trump administration's actions in health care settings.
This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.
This poll finds that about as many adults are turning to AI for health information as social media, with health care costs and access driving many users, particularly younger users.
This KFF survey is a follow-up survey of adults who had ACA Marketplace insurance in 2025. The survey examines the cost concerns and coverage changes that these 2025 Marketplace enrollees are experiencing following the expiration of the enhanced premium tax credits. The survey finds that half of returning enrollees say their health care costs are “a lot higher” and most expect to cut back on basic household expenses to afford coverage.
Amid the Trump administration's focus on lowering prescription drug costs, including its new TrumpRx website, KFF's Health Tracking Poll finds that most Americans (59%) are worried about affording prescription drugs and support more regulation of prescription drug pricing (72%). Looking ahead to the 2026 midterm elections, the Democratic party currently holds the advantage when it comes to who voters trust to address the cost of health care, including prescription drugs.
Weeks after the Trump administration reduced the number of childhood vaccine recommended for routine use, public trust in the CDC is at its lowest since the COVID-19 pandemic, and less than half are confident in federal agencies' ability to make such recommendations. Among those who have heard about the revised recommendations, more say they expect the changes to have a negative impact than a positive one on children’s health.
KFF's health tracking poll finds that beyond costs, insured adults say prior authorization is their biggest challenges when accessing care. About seven in ten (69%) insured adults say prior authorizations are burdensome, and a third (34%) choose prior authorizations as their single biggest health care burden.
Looking ahead to the midterm elections, health care costs are the public’s top economic concern, and many voters say the issue will have a major impact on their vote. On health care issues, including the cost of health care, voters currently trust Democrats more than Republicans, though neither party has an advantage on addressing the overall cost of living. Following the expiration of the ACA enhanced tax credits, two-thirds of the public say Congress did the “wrong thing” by not extending them.
As economic anxiety rises, KFF's Health Tracking Poll finds that younger adult, LGBT adults, Hispanic adults, and adults with modest incomes are among groups most likely to report difficulty earning a living and affording health care. Large shares of those who are uninsured or purchase their own insurance also report challenges earning a living and paying for care.
This KFF Health Tracking Poll finds that many, including women of reproductive age, remain unfamiliar with key facts about mifepristone. Fewer than half of all adults say they believe abortion pills are safe now, compared to over half of all adults two years ago. This poll explores awareness and perception of the recent FDA review of the medication, and support for policies aimed at restricting it.
© 2026 KFF